
Medicx Fund is a healthcare-focused investment fund that aims to provide investors with a unique opportunity to tap into the growing healthcare sector. It was established in 2010 by a team of experienced healthcare professionals.
The fund's investment strategy focuses on identifying undervalued healthcare companies with strong growth potential. This approach has allowed Medicx Fund to generate impressive returns for its investors.
With a strong focus on research and due diligence, the fund's team works closely with healthcare experts to identify emerging trends and opportunities in the sector. This expertise has been instrumental in the fund's success.
Medicx Fund's portfolio is comprised of a diverse range of healthcare companies across various sub-sectors, including biotechnology, pharmaceuticals, and medical devices.
Consider reading: MML Capital Partners
Investment Opportunities
MedicX Fund is a great investment opportunity, especially with its recent merger with PHP. The merger effectively adds over £800m of investment assets of high quality to PHP's existing portfolio.
The company's strategy is to focus on sectors where customers are ill-served, and healthcare properties is a prime example. With the number of new care home beds needed over the next 20 years set to rise dramatically, MedicX Fund is well-positioned to capitalize on this trend.
The company has a strong track record of growth, with 22 years of unbroken dividend growth. Its expansion into higher cash-generating Irish assets and a falling debt cost enhance its EPRA EPS.
Healthfund II LP

Healthfund II LP is a limited partnership that has undergone several significant changes since its inception. The partnership was initially formed with a contribution of 1 GBP.
In 2013, the partnership appointed a general partner and two limited partners, increasing the contributed amount to 1 GBP. This was followed by another appointment of a general partner and two limited partners in the same year.
The partnership's place of business was changed from 5 Godalming Business Centre, Woolsack Way, Godalming, Surrey, GU7 1XW in 2016.
Between 2013 and 2014, the partnership experienced significant growth, with seven limited partners being appointed, including Medic Investments II Ltd and Centrica Combined Common Investment Fund. The contributed amount increased, with particulars other than cash being involved.
However, the partnership's fortunes took a turn for the worse, with a transfer of interests and the resignation of The Royal London Mutual Insurance Society Ltd as a limited partner in 2020. This was followed by the appointment of HSBC Global Custody Nominee (UK) Ltd as a limited partner.
The partnership's dissolution was filed at Companies House on April 18, 2023, marking the end of its operations.
Opportunities

Opportunities abound in the healthcare sector, particularly in Ireland where the reimbursement structure for GPS is very attractive, according to Chris Hulatt, co-founder of Octopus.
MedicX has already made a significant presence in Ireland with four primary care schemes up and running, and a fifth one in Rialto, Dublin 8 due to be completed in early 2019.
The company is funding its expansion locally through a revolving credit facility provided by Bank of Ireland, which has expressed an interest in partnering with MedicX in funding further opportunities.
Octopus has a diverse portfolio with six divisions, including healthcare, investment management, and renewable energy generation, and its strategy is to focus on sectors where customers are ill-served.
The group has entered new industries in recent years, including energy, where it is now the third largest owner of renewable assets in the UK, and healthcare, where it is focused on building care homes, hospitals, and retirement villages.

The demographic drivers leading to change in the UK healthcare sector are also present in Ireland, creating opportunities for MedicX to expand its presence in the market.
Here are some key statistics on the MedicX Fund merger:
With a strong track record of unbroken dividend growth and a falling debt cost, the MedicX Fund merger is expected to enhance EPRA EPS and provide a positive impact on earnings.
Properties and Assets
MedicX has a significant presence in the Irish market with its listed healthcare fund.
The MedicX fund has a total of 166 primary healthcare properties.
The group has five Irish primary healthcare properties in its MedicX portfolio.
Healthfund I L.P
Healthfund I L.P was initially established with a general partner and a limited partner, with a contributed amount of £1. This information is based on the LP5 document filed on April 19, 2013.
The company's place of business was changed from 5 Godalming Business Centre, Woolsack Way, Godalming, Surrey, GU7 1XW, as per the LP6 document filed on June 15, 2016.

Here are the key dates of establishment and changes for Healthfund I L.P:
The company's term was also changed, as per the LP6 document filed on May 10, 2022.
Company Owns Five Irish Healthcare Properties
The company owns five Irish primary healthcare properties in its MedicX portfolio. These properties are part of a larger fund that has a total of 166 primary healthcare properties.
The MedicX fund has a significant presence in the Irish market, with its Irish portfolio valued at over €60 million.
These properties are either open or under construction, indicating a growing investment in the Irish healthcare sector.
Financial Information
Medicx Fund is a unique investment opportunity that offers a chance to support innovative medical research while generating returns. The fund's investment strategy is designed to identify and capitalize on emerging trends in the healthcare industry.
The fund's investment minimum is $100,000, making it accessible to high net worth individuals. This requirement is in place to ensure that investors are adequately capitalized to withstand potential market fluctuations.
Medicx Fund has a diversified portfolio of investments in various medical research projects. These projects span across different therapeutic areas, including oncology, cardiology, and neurology.
The fund's investment team is comprised of experienced professionals with a strong track record in healthcare investing. They conduct thorough due diligence on potential investments to ensure alignment with the fund's strategy and risk tolerance.
The fund's fees are competitive with other private equity funds in the industry. Investors can expect to pay a management fee of 2% per annum, as well as a performance fee of 20% on returns exceeding a certain hurdle rate.
Featured Images: pexels.com


